CRISPR Therapeutics
CRSP · NASDAQ
Bulios Fair Price
$50.32
9.2% downside
Trenutna cena
$55.43
Po podatkih Bulios Fair Price je delnica CRSP trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
CRISPR Therapeutics AG is a Swiss biotechnology company specializing in the development of therapeutics based on the revolutionary CRISPR-Cas9 technology. This technology enables precise and efficient editing of genetic material, opening up new possibilities in treating genetic diseases and other conditions. CRISPR Therapeutics focuses its research on the treatment of various genetic disorders, including beta-thalassemia and muscular dystrophy. The company collaborates with renowned scientific institutions and experts to strengthen its research and develop new therapeutic approaches. CRISPR Therapeutics AG is an innovative player in the biotechnology industry and is committed to bringing revolutionary treatments to patients with genetic diseases. CRISPR Therapeutics AG (CRSP) shares represent an attractive investment opportunity for investors who follow the biotechnology sector and seek an innovative company engaged in treating genetic disorders.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Samarth Kulkarni
Employees
393
Headquarters
Zug
Prihajajoči dogodki
Earnings
Upcoming earnings report